Wave Life Sciences Newsroom

Wave Life Sciences: Strategic Initiatives and Promising Milestones Drive Buy Rating

TipRanksJan 15 02:13 ET · Ratings

Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsJan 13 20:32 ET · Ratings

Wave Life Sciences Advances in RNA Editing Innovations

TipRanksJan 13 14:27 ET

Wave Life Sciences Announces 2025 Plans, Phase 1 INLIGHT Trial For Obesity Target WVE-007; RNA Editing Advancements With WVE-006; Regulatory Feedback And 48-Week Data For WVE-N531 In DMD Expected Q1 2025; Phase 2/3 Study For HD Treatment WVE-003 In...

BenzingaJan 13 09:31 ET

Wave Life Sciences Announces Key Milestones and Expansion of RNA Medicines Pipeline Heading Into 2025

Quiver QuantitativeJan 13 09:14 ET

Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

GlobeNewswireJan 13 09:00 ET

With A 25% Price Drop For Wave Life Sciences Ltd. (NASDAQ:WVE) You'll Still Get What You Pay For

Simply Wall StJan 11 08:26 ET

Is Wave Life Sciences Ltd. (WVE) the Best Growth Stock to Buy Now Under $25?

Yahoo FinanceJan 9 17:10 ET

Wave Life Sciences (NASDAQ:WVE) Shareholder Returns Have Been Massive, Earning 364% in 3 Years

Simply Wall StJan 7 10:24 ET

Wave Life Sciences' WVE-007: A Promising New Player in Obesity Treatment

TipRanksDec 25, 2024 06:55 ET

Wave Life Sciences (WVE) Gets a Buy From Truist Financial

TipRanksDec 24, 2024 07:15 ET · Ratings

Express News | Wave Life Sciences Ltd - Expects First-in-Human Study of Wve-007 in Q1 2025

ReutersDec 23, 2024 08:31 ET

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (SiRNA Targeting INHBE) in Obesity

GlobeNewswireDec 23, 2024 08:30 ET

Express News | Wave Life Sciences Announces Submission of First Clinical Trial Application for Wve-007 (Sirna Targeting Inhbe) in Obesity

ReutersDec 23, 2024 08:30 ET

PepGen Stock Craters 35% on FDA Clinical Hold

Seeking AlphaDec 16, 2024 09:56 ET

Buy Rating for Wave Life Sciences: Favorable Regulatory Environment and Promising WVE-003 Data

TipRanksDec 11, 2024 23:55 ET · Ratings

Wave Life Sciences: Positioned for Growth With Promising Huntington's Treatment and Strategic Advantages

TipRanksDec 5, 2024 12:08 ET

Insider Sale: President and CEO of $WVE (WVE) Sells 50,000 Shares

Quiver QuantitativeNov 27, 2024 21:15 ET

Wave Life Sciences CEO Paul Bolno Sells $750,000 in Shares

Investing.com Nov 27, 2024 21:02 ET

Truist Financial Maintains Wave Life Sciences(WVE.US) With Buy Rating

Moomoo NewsNov 27, 2024 07:33 ET · Ratings